Hi-Tech Pharmacal to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

  Hi-Tech Pharmacal to Present at the Bank of America Merrill Lynch 2013
  Health Care Conference

Bank of America Merrill Lynch 2013 Healthcare Conference

Business Wire

AMITYVILLE, N.Y. -- May 09, 2013

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is
scheduled to make an investor presentation at the Bank of America Merrill
Lynch Health Care Conference on Tuesday, May 14, 2013, at 10:00 a.m. Pacific

A live audio webcast of the Company's presentation can be accessed on the
Investor Relations page of the Company’s website:


The webcast will be archived within one hour after the live event and will be
available for 90 days.

About Hi-Tech Pharmacal

Hi-Tech Pharmacal is a specialty pharmaceutical company developing,
manufacturing and marketing generic and branded products. The Company
specializes in difficult to manufacture liquid and semi-solid dosage forms and
produces a range of sterile ophthalmic, otic and inhalation products. The
Company’s Health Care Products Division is a leading developer and marketer of
branded prescription and OTC products for the diabetes marketplace. Hi-Tech’s
ECR Pharmaceuticals subsidiary markets branded prescription products.

This press release contains certain future projections and forward-looking
statements (statements which are not historical facts) with respect to the
anticipated future performance of Hi-Tech made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Such
future projections and forward-looking statements are not assurances, promises
or guarantees and investors are cautioned that all future projections and
forward-looking statements involve significant business, economic and
competitive risks and uncertainties, many of which are beyond Hi-Tech's
ability to control or estimate precisely, including, but not limited to, the
impact of competitive products and pricing, product demand and market
acceptance, new product development, the regulatory environment, including
without limitation, reliance on key strategic alliances, availability of raw
materials, fluctuations in operating results, loss of customers or employees,
the possibility that legal proceedings may be instituted against Hi-Tech and
other results and other risks detailed from time to time in Hi-Tech's filings
with the Securities and Exchange Commission. The actual results will vary from
the projected results and such variations may be material. These statements
are based on management's current expectations and assumptions concerning the
future performance of Hi-Tech and are naturally subject to uncertainty and
changes in circumstances. No representations or warranties are made as to the
accuracy or completeness of any of the information contained herein,
including, but not limited to, any assumptions or projections contained herein
or forward-looking statements based thereon. We caution you not to place undue
reliance upon any such forward-looking statements which speak only as of the
date made, except to the extent specifically dated as of an earlier date.
Hi-Tech is under no obligation, and expressly disclaims any such obligation,
to update, alter or correct any inaccuracies herein, whether as a result of
new information, future events or otherwise.


Hi-Tech Pharmacal Co., Inc.
Bill Peters, 631-789-8228
Press spacebar to pause and continue. Press esc to stop.